Glenmark’s arm gets approval from USFDA for Sevelamer Hydrochloride Tablets

11 Feb 2019 Evaluate

Glenmark Pharmaceuticals – subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg, a generic version of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation.

According to IQVIA sales data for the 12 month period ending December 2018, the Renagel Tablets, 400 mg and 800 mg market achieved annual sales of approximately $102.1 million.

The company’s current portfolio consists of 149 products authorized for distribution in the US market place and 53 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

1943.35 9.10 (0.47%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×